TTD Drug ID: DNC014806

Drug Information
Name	ARC-1028
Indication	Not Available			Experimental
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
InChI	1S/C64H118N34O13/c65-24-6-5-15-36(91-42(99)22-4-2-8-26-81-57(110) 47-45(101)46(102)58(111-47)98-34-90-44-48(66)88-33-89-50(44)98)51 (104)80-25-7-1-3-23-43(100)92-37(17-10-28-83-60(70)71)52(105)94-3 9(19-12-30-85-62(74)75)54(107)96-41(21-14-32-87-64(78)79)56(109)9 7-40(20-13-31-86-63(76)77)55(108)95-38(18-11-29-84-61(72)73)53(10 6)93-35(49(67)103)16-9-27-82-59(68)69/h33-41,45-47,58,101-102H,1- 32,65H2,(H2,67,103)(H,80,104)(H,81,110)(H,91,99)(H,92,100)(H,93,1 06)(H,94,105)(H,95,108)(H,96,107)(H,97,109)(H2,66,88,89)(H4,68,69 ,82)(H4,70,71,83)(H4,72,73,84)(H4,74,75,85)(H4,76,77,86)(H4,78,79 ,87)/t35-,36-,37-,38-,39-,40-,41-,45+,46-,47+,58-/m1/s1
InChIKey	FBAPHDWTBAGCKW-LJDCWIOTSA-N
Canonical SMILES	C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)C(=O)NCCCCCC(=O)NC(CCCCN)C(=O)NCCCCCC(= O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N) N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)N)O)O
Isomeric SMILES	C1=NC2=C(C(=N1)N)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@ H](CCCCN)C(=O)NCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N [C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@ H](CCCN=C(N)N)C(=O)N)O)O
Target	cGMP-dependent protein kinase 1 beta			Inhibitor	[1]
Ref 1	J Med Chem. 2009 Jan 22;52(2):308-21.Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. To Reference

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.